Shots: EC has released Takeda from the obligation to divest SHP647 & its associated rights. Takeda will discontinue the clinical study of SHP647 and will provide an opportunity to the participants to access in a PTA study In 2018, EC approved its proposed acquisition of Shire with a condition. To avoid overlap in IBD b/w […]Read More
